Sensitization of lung cancer cells to cisplatin by β-elemene is mediated through blockade of cell cycle progression

Antitumor efficacies of β-elemene and its synthetic analogs

Q. Quentin Li, Gangduo Wang, Furong Huang, Jueli M. Li, Christopher F. Cuff, Eddie Reed

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The development of effective agents for overcoming platinum chemoresistance in lung carcinoma continues to have high priority. We have demonstrated recently that β-elemene, a novel antitumor compound, enhances cisplatin activity by triggering lung cancer cell death via apoptosis. Here, we investigated whether β-elemene acts synergistically with cisplatin to inhibit non-small cell lung cancer (NSCLC) cell proliferation by blocking cell cycle progression. β-Elemene substantially increased the suppressive effect of cisplatin on cell growth and proliferation in the NSCLC cell lines H460 and A549. Furthermore, β-elemene augmented cisplatin in the cell cycle arrest of NSCLC cells at G2/M. This was associated with upregulated checkpoint kinase (CHK2) expression and reduced CDC2 activity (i.e., increased phosphorylation of CDC2 on Tyr-15 and decreased phosphorylation of CDC2 on Thr-161). Moreover, β-elemene and cisplatin in combination clearly decreased the protein levels of cyclin B1 and CDC25C and increased the levels of p21Cip1/Waf1, p27Kip1, and GADD45 in these cells, compared with the effects of either agent alone at the same concentration. These results suggest that the β-elemene-enhanced inhibitory effect of cisplatin on lung carcinoma cell proliferation is regulated by a CHK2-mediated CDC25C/CDC2/cyclin B1 signaling pathway and leads to the blockade of cell cycle progression at G2/M. A comparison of the cytotoxic efficacies of β-elemene and three synthetic analogs (β-elemenol, β-elemenal, and β-elemene fluoride) in the two lung cancer cell lines revealed that β-elemenol and β-elemene fluoride had the same antitumor efficacy as β-elemene, whereas β-elemenal was appreciably more potent than β-elemene. Thus, although all three synthetic analogs of β-elemene considerably suppressed NSCLC cell growth and proliferation, β-elemenal may have greater potential as an anticancer alternative to β-elemene in treating lung cancer and other tumors.

Original languageEnglish (US)
Article number488
JournalMedical Oncology
Volume30
Issue number1
DOIs
StatePublished - Mar 2013
Externally publishedYes

Fingerprint

Cisplatin
Lung Neoplasms
Cell Cycle
Non-Small Cell Lung Carcinoma
Cell Proliferation
Cyclin B1
Fluorides
elemene
Phosphorylation
Carcinoma
Lung
Growth
Cell Cycle Checkpoints
Platinum
Cell Death
Phosphotransferases
Apoptosis
Cell Line

Keywords

  • β-Elemene
  • Cell cycle arrest
  • Chinese medicine
  • Cisplatin resistance
  • Lung cancer
  • Synthetic analogs

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology
  • Medicine(all)

Cite this

Sensitization of lung cancer cells to cisplatin by β-elemene is mediated through blockade of cell cycle progression : Antitumor efficacies of β-elemene and its synthetic analogs. / Li, Q. Quentin; Wang, Gangduo; Huang, Furong; Li, Jueli M.; Cuff, Christopher F.; Reed, Eddie.

In: Medical Oncology, Vol. 30, No. 1, 488, 03.2013.

Research output: Contribution to journalArticle

@article{b5f12528366c4d2394ce1d1dcd8ec983,
title = "Sensitization of lung cancer cells to cisplatin by β-elemene is mediated through blockade of cell cycle progression: Antitumor efficacies of β-elemene and its synthetic analogs",
abstract = "The development of effective agents for overcoming platinum chemoresistance in lung carcinoma continues to have high priority. We have demonstrated recently that β-elemene, a novel antitumor compound, enhances cisplatin activity by triggering lung cancer cell death via apoptosis. Here, we investigated whether β-elemene acts synergistically with cisplatin to inhibit non-small cell lung cancer (NSCLC) cell proliferation by blocking cell cycle progression. β-Elemene substantially increased the suppressive effect of cisplatin on cell growth and proliferation in the NSCLC cell lines H460 and A549. Furthermore, β-elemene augmented cisplatin in the cell cycle arrest of NSCLC cells at G2/M. This was associated with upregulated checkpoint kinase (CHK2) expression and reduced CDC2 activity (i.e., increased phosphorylation of CDC2 on Tyr-15 and decreased phosphorylation of CDC2 on Thr-161). Moreover, β-elemene and cisplatin in combination clearly decreased the protein levels of cyclin B1 and CDC25C and increased the levels of p21Cip1/Waf1, p27Kip1, and GADD45 in these cells, compared with the effects of either agent alone at the same concentration. These results suggest that the β-elemene-enhanced inhibitory effect of cisplatin on lung carcinoma cell proliferation is regulated by a CHK2-mediated CDC25C/CDC2/cyclin B1 signaling pathway and leads to the blockade of cell cycle progression at G2/M. A comparison of the cytotoxic efficacies of β-elemene and three synthetic analogs (β-elemenol, β-elemenal, and β-elemene fluoride) in the two lung cancer cell lines revealed that β-elemenol and β-elemene fluoride had the same antitumor efficacy as β-elemene, whereas β-elemenal was appreciably more potent than β-elemene. Thus, although all three synthetic analogs of β-elemene considerably suppressed NSCLC cell growth and proliferation, β-elemenal may have greater potential as an anticancer alternative to β-elemene in treating lung cancer and other tumors.",
keywords = "β-Elemene, Cell cycle arrest, Chinese medicine, Cisplatin resistance, Lung cancer, Synthetic analogs",
author = "Li, {Q. Quentin} and Gangduo Wang and Furong Huang and Li, {Jueli M.} and Cuff, {Christopher F.} and Eddie Reed",
year = "2013",
month = "3",
doi = "10.1007/s12032-013-0488-9",
language = "English (US)",
volume = "30",
journal = "Medical oncology (Northwood, London, England)",
issn = "1357-0560",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Sensitization of lung cancer cells to cisplatin by β-elemene is mediated through blockade of cell cycle progression

T2 - Antitumor efficacies of β-elemene and its synthetic analogs

AU - Li, Q. Quentin

AU - Wang, Gangduo

AU - Huang, Furong

AU - Li, Jueli M.

AU - Cuff, Christopher F.

AU - Reed, Eddie

PY - 2013/3

Y1 - 2013/3

N2 - The development of effective agents for overcoming platinum chemoresistance in lung carcinoma continues to have high priority. We have demonstrated recently that β-elemene, a novel antitumor compound, enhances cisplatin activity by triggering lung cancer cell death via apoptosis. Here, we investigated whether β-elemene acts synergistically with cisplatin to inhibit non-small cell lung cancer (NSCLC) cell proliferation by blocking cell cycle progression. β-Elemene substantially increased the suppressive effect of cisplatin on cell growth and proliferation in the NSCLC cell lines H460 and A549. Furthermore, β-elemene augmented cisplatin in the cell cycle arrest of NSCLC cells at G2/M. This was associated with upregulated checkpoint kinase (CHK2) expression and reduced CDC2 activity (i.e., increased phosphorylation of CDC2 on Tyr-15 and decreased phosphorylation of CDC2 on Thr-161). Moreover, β-elemene and cisplatin in combination clearly decreased the protein levels of cyclin B1 and CDC25C and increased the levels of p21Cip1/Waf1, p27Kip1, and GADD45 in these cells, compared with the effects of either agent alone at the same concentration. These results suggest that the β-elemene-enhanced inhibitory effect of cisplatin on lung carcinoma cell proliferation is regulated by a CHK2-mediated CDC25C/CDC2/cyclin B1 signaling pathway and leads to the blockade of cell cycle progression at G2/M. A comparison of the cytotoxic efficacies of β-elemene and three synthetic analogs (β-elemenol, β-elemenal, and β-elemene fluoride) in the two lung cancer cell lines revealed that β-elemenol and β-elemene fluoride had the same antitumor efficacy as β-elemene, whereas β-elemenal was appreciably more potent than β-elemene. Thus, although all three synthetic analogs of β-elemene considerably suppressed NSCLC cell growth and proliferation, β-elemenal may have greater potential as an anticancer alternative to β-elemene in treating lung cancer and other tumors.

AB - The development of effective agents for overcoming platinum chemoresistance in lung carcinoma continues to have high priority. We have demonstrated recently that β-elemene, a novel antitumor compound, enhances cisplatin activity by triggering lung cancer cell death via apoptosis. Here, we investigated whether β-elemene acts synergistically with cisplatin to inhibit non-small cell lung cancer (NSCLC) cell proliferation by blocking cell cycle progression. β-Elemene substantially increased the suppressive effect of cisplatin on cell growth and proliferation in the NSCLC cell lines H460 and A549. Furthermore, β-elemene augmented cisplatin in the cell cycle arrest of NSCLC cells at G2/M. This was associated with upregulated checkpoint kinase (CHK2) expression and reduced CDC2 activity (i.e., increased phosphorylation of CDC2 on Tyr-15 and decreased phosphorylation of CDC2 on Thr-161). Moreover, β-elemene and cisplatin in combination clearly decreased the protein levels of cyclin B1 and CDC25C and increased the levels of p21Cip1/Waf1, p27Kip1, and GADD45 in these cells, compared with the effects of either agent alone at the same concentration. These results suggest that the β-elemene-enhanced inhibitory effect of cisplatin on lung carcinoma cell proliferation is regulated by a CHK2-mediated CDC25C/CDC2/cyclin B1 signaling pathway and leads to the blockade of cell cycle progression at G2/M. A comparison of the cytotoxic efficacies of β-elemene and three synthetic analogs (β-elemenol, β-elemenal, and β-elemene fluoride) in the two lung cancer cell lines revealed that β-elemenol and β-elemene fluoride had the same antitumor efficacy as β-elemene, whereas β-elemenal was appreciably more potent than β-elemene. Thus, although all three synthetic analogs of β-elemene considerably suppressed NSCLC cell growth and proliferation, β-elemenal may have greater potential as an anticancer alternative to β-elemene in treating lung cancer and other tumors.

KW - β-Elemene

KW - Cell cycle arrest

KW - Chinese medicine

KW - Cisplatin resistance

KW - Lung cancer

KW - Synthetic analogs

UR - http://www.scopus.com/inward/record.url?scp=84873391545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873391545&partnerID=8YFLogxK

U2 - 10.1007/s12032-013-0488-9

DO - 10.1007/s12032-013-0488-9

M3 - Article

VL - 30

JO - Medical oncology (Northwood, London, England)

JF - Medical oncology (Northwood, London, England)

SN - 1357-0560

IS - 1

M1 - 488

ER -